BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
GlobeNewswire
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination..
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination..
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic..
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2023" report has been added to *..